Dasotraline
- Generic Name
- Dasotraline
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15Cl2N
- CAS Number
- 675126-05-3
- Unique Ingredient Identifier
- 4D28EY0L5T
- Background
Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and Adult Attention Deficit Hyperactivity Disorder.
Open-label Safety Study in Adults With ADHD
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 724
- Registration Number
- NCT02160262
- Locations
- 🇺🇸
Premeir Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States
🇺🇸Pillar Clinical Research, LLC, Dallas, Texas, United States
🇺🇸Family Psychiatry of the Woodlands, The Woodlands, Texas, United States
Adult Attention Deficit Hyperactivity Disorder
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2015-01-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 341
- Registration Number
- NCT01692782
- Locations
- 🇺🇸
University of California at Irvine, Irvine, California, United States
🇺🇸Collaborative Neuroscience Network Inc, Garden Grove, California, United States
🇺🇸Excell Research, Inc, Oceanside, California, United States
A Safety, Efficacy and Tolerability Study of SEP-225289
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2008-01-02
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 523
- Registration Number
- NCT00584974
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.